AbbVie (NYSE:ABBV) Shares Up 4.3% – What’s Next?

AbbVie Inc. (NYSE:ABBV) rose 4.3% on Wednesday . The stock traded as high as $237.04 and last traded at $233.65. Approximately 9,772,217 shares changed hands during mid-day trading, an increase of 24% from the average daily volume of 7,895,978 shares. The stock had previously closed at $223.93.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reported to be in advanced talks to acquire Revolution Medicines, a clinical‑stage oncology biotech with a market value around $16 billion — a deal would add KRAS/targeted oncology assets and justify an acquisition premium. AbbVie in talks to buy biotech Revolution Medicines, WSJ reports (via Reuters) AbbVie Near Deal for Revolution Medicines (WSJ)
• Positive Sentiment: AbbVie expanded its ovarian‑cancer pipeline by opening a first‑in‑human ABBV‑901 Phase 1 trial, which strengthens the company’s oncology R&D narrative and may support longer‑term growth expectations. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Neutral Sentiment: Ironwood Pharmaceuticals’ guidance shock and its decision to cut LINZESS list price (effective Jan. 1) was a catalyst for Ironwood’s rally; Ironwood is partnered with AbbVie on LINZESS — the direct financial impact for AbbVie is unclear and appears neutral for now. Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re‑Rating
• Neutral Sentiment: AbbVie scheduled its full‑year and fourth‑quarter 2025 earnings release for Feb. 4, 2026; investors will watch guidance and any comments on M&A strategy, pipeline timing, and margins. AbbVie to Host Full‑Year and Fourth‑Quarter 2025 Earnings Conference Call
• Neutral Sentiment: Analyst coverage remains mixed—UBS reiterated a Hold on AbbVie citing premium valuation balanced against long‑duration growth; this tempers upside expectations absent clear M&A terms or big pipeline readouts. AbbVie: Premium Valuation, Strong Long‑Duration Growth, but Balanced Risk/Reward Supports Hold Rating
• Negative Sentiment: Competitive marketing dynamics: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads in December, a reminder that market share in immunology faces aggressive competitor promotion. J&J’s Tremfya outstrips AbbVie’s Skyrizi again

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Morgan Stanley upped their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. BMO Capital Markets lifted their price target on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Finally, Piper Sandler reissued an “overweight” rating and issued a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Stock Up 4.3%

The stock has a market cap of $412.95 billion, a P/E ratio of 177.01, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The firm’s 50 day simple moving average is $226.46 and its two-hundred day simple moving average is $214.67.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is presently 496.97%.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA acquired a new position in AbbVie during the second quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the 3rd quarter worth approximately $26,000. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the second quarter valued at approximately $28,000. Finally, Texas Capital Bancshares Inc TX acquired a new stake in AbbVie during the third quarter valued at approximately $31,000. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.